Compare · KRRO vs NVO
KRRO vs NVO
Side-by-side comparison of Korro Bio Inc. (KRRO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRRO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1065.7x KRRO ($202.2M).
- Over the past year, KRRO is down 32.4% and NVO is down 12.1% - NVO leads by 20.3 points.
- KRRO has been more active in the news (10 items in the past 4 weeks vs 9 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Korro Bio Inc.
- Novo Nordisk A/S
- Price
- $13.69+4.86%
- $48.65+3.65%
- Market cap
- $202.2M
- $215.46B
- 1M return
- +27.82%
- -2.08%
- 1Y return
- -32.38%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 10
- 9
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KRRO
- Director Formela Jean Francois sold $398,552 worth of shares (28,468 units at $14.00) as part of a pre-agreed trading plan (SEC Form 4)
- Korro Bio Inc. filed SEC Form 8-K: Other Events
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.
- Director Formela Jean Francois sold $29,916 worth of shares (2,143 units at $13.96) as part of a pre-agreed trading plan (SEC Form 4)
- Large owner Lynx1 Capital Management Lp bought $78,809 worth of shares (6,684 units at $11.79) (SEC Form 4)
- SEC Form 10-Q filed by Korro Bio Inc.
- Korro Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- President and CEO Aiyar Ram sold $62,917 worth of shares (5,802 units at $10.84), decreasing direct ownership by 8% to 69,046 units (SEC Form 4) (tax liability)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S